CLINICAL APPLICATION OF PROTEINOUS KINASE C IN ORDER TO INCREASE CLINICAL EFFECTIVENESS OF ANTICARCINOGENIC PHARMACO- AND RADIOTHERAPY

摘要

A method for treating neoplasms is disclosed, particularly using the beta-isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2''-ethoxy)-3'''(O)-4'''-(N,N -dimethylamino)butane)-bis-(3,3'-indolyl)]-1(H)-pyrrole-2,5-dione or one of its salts, such PKC inhibitors enhance the clinical efficacy of oncolytic agents and radiation therapy.